KindlyMD, Inc.

NAKA Financial Capital Markets

KindlyMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.8 million, down 33.0% from fiscal 2024. In the quarter to June 2026, revenue grew 8,680.7%, EPS grew 52.5% and free cash flow fell 25.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.13 0.96 −11.87%
Market cap
$144.8M
P/E
0.0×
Fwd P/E
−0.5×
Dividend yield
—
F-score
3/9
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a

Insider Decisions trades per month

Total buys 1.23
Total sells 0.01
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 2 — — 2 — —
Sell — — — — — — — — — — 1 —
Insider Ownership 45.85%

Capital & Financial Ratios $m

Market Cap 144.77
Revenue 39.79
Net Income (420.55)
Free Cash Flow (687.94)
Net Debt (19.07)
Current Ratio 0.15
Debt/Equity 0.00
P/E ratio 0.00
Fwd P/E (0.47) (negative: loss-making)
P/S ratio 3.58
P/B ratio 0.60
Past 5Y EPS Growth —
This Y EPS Growth 23.94% (at or above 15%: strong)
Next Y EPS Growth 86.89% (at or above 15%: strong)
Next Y revenue growth 3,834.00% (at or above 10%: strong)
Next 5Y EPS Growth 62.35% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 2 23 19
Receivables 0 0 — —
Inventory 0 0 — —
Other — — 199 4
1 3 224 27
2023 2024 2025 Q'26
Payables 0 0 6 11
ST’ Debt — — — —
Other 0 0 1 4
1 1 216 179

Compound Annual Growth %

10y 5y 3y
Sales — — —
Cash Flow — — —
Earnings — — —
Book Value — — —

Revenue $m

Mar Jun Sep Dec Year
’26 3 36 — — —
’25 1 0 0 1 2
’24 1 1 1 1 3
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (23) (3) — — —
’25 (1) (2) (13) (8) (24)
’24 0 (1) (1) (1) (3)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (7) (5) — — —
’25 (1) (4) (655) (21) (679)
’24 0 (1) (1) (1) (3)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (15.20) (6.65) — — —
’25 (6.80) (14.00) (16.80) 2.80 (10.40)
’24 (2.40) (10.40) (6.80) (6.80) (26.80)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — — — 26.00 13.72

Analyst estimates 2026–2028

Powerpack
High — — — — — — — — 168.00 1,390.80
People
People Employees — — — — — — — — 61 65
Revenue/emp, $m — — — — — — — 0.00 0.04 0.03
Income, $m
Income, $m Revenue — — — — — — — 4 3 2
Gross margin, % — — — — — — — 94.00 100.00 100.00
EBT — — — — — — — (2) (4) (52)
EBT margin, % — — — — — — — (42.92) (133.01) (2,867.67)
Net income — — — — — — — (2) (4) (52)
Depreciation — — — — — — — 0 1 3
Per share, $
Per share, $ Revenue — — — — — — — 33.50 20.18 0.36
Earnings — — — — — — — (14.38) (26.80) (10.40)
Cash flow — — — — — — — (4.00) (22.80) (4.70)
Capex — — — — — — — (0.13) (2.98) (130.92)
Free cash flow — — — — — — — (4.12) (25.78) (135.62)
Book value — — — — — — — (0.96) 19.05 102.75
Shares, m — — — — — — — 0 0 5
Valuation, ×
Valuation, × P/E — — — — — — — 0.00 0.00 0.00
P/S — — — — — — — 4.06 2.46 31.51
P/B — — — — — — — 0.00 2.60 0.14
EV/Sales — — — — — — — 4.02 1.63 22.07
EV/FCF — — — — — — — (16.42) (1.27) (0.07)
Cash, $m
Cash, $m Operating cash flow — — — — — — — 0 (3) (24)
Capex — — — — — — — 0 0 (655)
Free cash flow — — — — — — — 0 (3) (679)
Balance, $m
Balance, $m Working capital — — — — — — — 0 2 8
Total debt — — — — — — — 0 0 —
Net debt — — — — — — — 0 (2) (23)
Shareholders’ equity — — — — — — — 0 3 514
Returns, %
Returns, % ROA — — — — — — — 0.00 (151.45) (14.23)
ROIC — — — — — — — 0.00 (691.95) (25.06)
ROE — — — — — — — 0.00 (294.13) (20.21)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

KindlyMD, Inc. vs peers in Capital Markets (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
FUFU BitFuFu Inc. $218.3M — (loss-making) — (loss-making) −62.94% (below 0%: shrinking) n/m +92.59% (above 0%: growing) (2.24%) (51.24%) Compare
AUC ATIF Holdings Limited $188.8M — (loss-making) — (loss-making) +275.00% (above 0%: growing) n/m −4,494.70% (below 0%: shrinking) 100.00% 29.15% Compare
SLNH Soluna Holdings, Inc. $183.8M — (loss-making) 23.6× +144.56% (above 0%: growing) n/m −124.94% (below 0%: shrinking) 5.09% (112.50%) Compare
DEFT DeFi Technologies Inc. $171.2M 7.2× — −40.69% (below 0%: shrinking) n/m −24.31% (below 0%: shrinking) 100.00% (22.78%) Compare
CANG Cango Inc. Sponsored ADR $156.3M — (loss-making) — (loss-making) −63.69% (below 0%: shrinking) n/m −145,939.21% (below 0%: shrinking) (33.17%) (158.75%) Compare
NAKA KindlyMD, Inc. $144.8M — (loss-making) — (loss-making) +8,680.66% (above 0%: growing) n/m −25.71% (below 0%: shrinking) 57.82% (415.62%)
WTF Waton Financial Limited $133.6M — — — — −161.72% (below 0%: shrinking) — — Compare
GSIW Garden Stage Limited $115.7M — — — — +38.83% (above 0%: growing) — — Compare
BMHL Bluemount Holdings Limited $91.4M — — — — −870.71% (below 0%: shrinking) — — Compare
Median of peers $163.7M — — −40.69% — −143.33% 5.09% (51.24%)

All 93 Capital Markets stocks →

KindlyMD, Inc. (NAKA) key facts

  • Concern: KindlyMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.8 million, down 33.0% from fiscal 2024.
  • KindlyMD, Inc. (NAKA) is a Capital Markets company in the Financial sector, listed on Nasdaq.
  • As of October 16, 2026, NAKA traded at $7.13, a market capitalization of $144.8 million.
  • Return on equity was −20.2% and debt-to-equity 0.00.
  • Its Piotroski F-score is 3 out of 9 for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

KindlyMD, Inc. (NAKA) Latest News

12 Dec

Impact 4 ·
stockrow.com/NAKA · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com